Glenmark Pharmaceuticals will launch Potassium Phosphates Injection USP, a bioequivalent to Fresenius Kabi's drug. The company will begin US distribution in March 2026, entering a market with annual sales of approximately $50.7 million.
Glenmark Pharmaceuticals Inc USA has announced the upcoming launch of 'Potassium Phosphates Injection USP', 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL single-dose vials and 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials.
Bioequivalent to Reference Drug
According to a statement released by the pharmaceutical company, "Glenmark's Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL Single-Dose Vials and 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL, 45 mmol P / 66 mEq K per 15 mL, and 150 mmol P / 220 mEq K per 50 mL of Fresenius Kabi [NDA 212832].
Market Size and Distribution Timeline
The release also stated that Glenmark will begin distribution in March 2026. According to the sales data from IQVIA, the Potassium Phosphates Injection market in the US recorded annual sales of about $50.7 million for the 12-month period ending January 2026.
Expanding US Injectable Portfolio
Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, "We look forward to growing our portfolio of products within the institutional channel with the upcoming launch of Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL Single-Dose Vials and 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials. We continue to strengthen our commitment to bring quality and affordable alternatives to market for patients in need with each injectable launch."
(Except for the headline, this story has not been edited by Asianet Newsable English staff and is published from a syndicated feed.)